or the offices of the Board of Governors not later than June 25, 1999.

A. Federal Reserve Bank of Dallas (W. Arthur Tribble, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. Independent Bankers Financial Corp., Irving, Texas, and Community Financial Services, Inc., Atlanta, Georgia; to engage *de novo* through their subsidiary, Internet Banking Communications, LLC, Atlanta, Georgia, in the development and marketing of software products and related services to financial institutions, § 225.28(b)(14) of Regulation Y.

Board of Governors of the Federal Reserve System, June 7, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99–14785 Filed 6–9–99; 8:45 am]

BILLING CODE 6210–01–F

GENERAL ACCOUNTING OFFICE

[Docket No. JFMIP–SR–99–7]

Joint Financial Management Improvement Program (JFMIP)–Federal Financial Management System Requirements (FFMSR)

AGENCY: Joint Financial Management Improvement Program (JFMIP).

ACTION: Notice of document availability.

SUMMARY: The JFMIP is seeking public comment on an exposure draft titled, ''Seized Property and Forfeited Assets System Requirements'' dated June 2, 1999. The draft is being issued to update a May 1993 document. The draft incorporates: (1) Statutory and regulatory changes; (2) technological changes; and (3) JFMIP documentation changes. The document is designed to provide financial managers with Governmentwide mandatory requirements for financial systems in order to process and record financial events effectively and efficiently, and to provide complete, timely, reliable, and consistent information for decision makers and the public.

DATES: Comments are due by August 13, 1999.

ADDRESSES: Copies of the exposure draft have been mailed to agency senior financial officials and are available on the JFMIP website: *http://www.financenet.gov/financenet/fed/jfmip/jfmipexp.htm*.

Comments should be addressed to JFMIP, 441 G Street NW, Room 3111, Washington, DC 20548.

FOR FURTHER INFORMATION CONTACT: Doris Chew, 202–512–9216 or via Internet: *chewd.jfmip@gao.gov*.

SUPPLEMENTARY INFORMATION: The Federal Financial Management Improvement Act (FFMIA) of 1996 mandated that agencies implement and maintain systems that comply substantially with Federal financial management systems requirements, applicable Federal accounting standards, and the U.S. Government Standard General Ledger at the transaction level. The FFMIA statute codified the JFMIP financial systems requirements documents as a key benchmark that agency systems must meet in order to be substantially in compliance with systems requirements provisions under FFMIA. To support the requirements outlined in the FFMIA, we are updating requirements documents that are obsolete and publishing additional requirements documents.

Comments received will be reviewed and the exposure draft will be revised as necessary. Publication of the final requirements will be mailed to agency senior financial officials and will be available on the JFMIP website.

Karen Cleary Alderman,

Executive Director, Joint Financial Management Improvement Program.

[FR Doc. 99–14652 Filed 6–9–99; 8:45 am]

BILLING CODE 1610–02–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 99145]

Hepatitis Education for Inmates and Correctional Staff; Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 1999 funds for a cooperative agreement with one or more national voluntary organizations involved with correctional facilities to develop and distribute materials to educate inmates and correctional staff about the risks of transmission and acquisition of viral hepatitis, as well as prevention, counseling, testing, and treatment of viral hepatitis, with an emphasis on hepatitis A, B, and C prevention and counseling. This program addresses the ''Healthy People 2000'' priority area of Immunization and Infectious Diseases.

The purpose of the program is to provide assistance for the development of educational materials that address the prevention, testing, counseling, and treatment of viral hepatitis (focus on the prevention of hepatitis A, B, and C virus infection including hepatitis B vaccination) in correctional settings in the United States. Specifically, applications are solicited for projects aimed at developing and distributing educational materials on viral hepatitis to inmates, and correctional staff.

B. Eligible Applicants

Applications may be provided only to organizations currently providing health education materials to correctional populations and health related training materials to staff of correctional institutions at a national or regional level.

Since the purpose of the program is to provide assistance for the development of educational materials that address the prevention, testing, counseling, and treatment of viral hepatitis in correctional settings in the United States, only applications from organizations that develop and distribute educational materials on viral hepatitis to inmates and correctional staff are solicited.

Note: Public Law 104–65 states that an organization described in section 501(c)(4) of the Internal Revenue Code of 1986 that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, cooperative agreement, contract, loan, or any other form.

C. Availability of Funds

Approximately $100,000 is available in FY 1999 to fund up to 3 awards. It is expected that the average award will be $35,000, ranging from $25,000 to $40,000. It is expected that the award(s) will begin on or about September 30, 1999, and will be made for a 12-month budget period within a project period of up to three years. Funding estimates may change.

Continuation awards within an approved project period will be made on the basis of satisfactory progress as evidenced by required reports and the availability of funds.

Funding Preference

A preference will be given to applicants with access to inmates and corrections staff at local, state, and/or federal (public and private) corrections programs with a demonstrated high concentration of inmates and corrections staff at high risk for viral hepatitis infection.

D. Program Requirements

In conducting activities to achieve the purpose of this program, the recipient will be responsible for the activities under 1. below, and CDC will be

responsible for the activities listed under 2. below:

1. Recipient Activities.

a. Conduct a needs assessment to demonstrate a genuine and compelling need for educational materials for inmates and correctional staff. At the conclusion of the needs assessment, begin to develop appropriate educational materials.

b. Develop educational materials on prevention, testing, counseling, and treatment for inmates in all types of correctional settings. The applicant may include formative research and focus group testing of materials. The central focus of these educational materials should be the prevention of hepatitis A, B, and C virus infection including hepatitis B vaccination.

c. Develop appropriate materials specific to the needs of this inmate and correctional staff population and correlate with the needs assessment done in the first year.

d. Develop an inmate education curriculum emphasizing risk-reduction, specific to the prevention of viral hepatitis.

e. Evaluate the program established to determine pre- and post-education knowledge about the prevention of hepatitis.

2. CDC Activities.

a. Provide technical information for all forms of viral hepatitis including information about current testing, modes of transmission, treatment, vaccinations, and complications.

b. Provide assistance in the development and distribution of the educational materials for both inmates and correctional staff.

c. Provide the source of information for these educational materials.

d. Assist in the development of a research protocol for IRB review by all cooperating institutions participating in the research project. The CDC IRB will review and approve the protocol initially an or at least on an annual basis until the research project is completed.

E. Application Content

Use the information in the Program Requirements, Other Requirements, and Evaluation Criteria sections to develop the application content. Your application will be evaluated on the criteria listed, so it is important to follow them in laying out your program plan. The narrative should be no more than 20 double-spaced pages, printed on one side, with one inch margins, and unreduced 12 cpi font.

Include the following in the narrative section of your application:

1. Program objectives that respond to the program requirements outlined in this announcement.

2. An operational plan that describes how the objectives will be achieved.

3. An evaluation plan that includes qualitative and quantitative measures to assess the effectiveness of the program in accomplishing your program objectives.

4. A projected time line for conducting the proposed program and evaluation activities.

5. A description of personnel that includes current and proposed staff with position titles, position descriptions, and percentage of time staff person will devote to assigned project responsibilities. Also, include a curriculum vitae of new staff.

6. A detailed, line-item budget for the project and a budget narrative that justifies each line-item.

F. Submission and Deadline

Submit the original and two copies of PHS 5161–1 (OMB Number 0937–0189). Forms are available in the application kit. On or before July 23, 1999, submit the application to the Grants Management Specialist identified in the ''Where to Obtain Additional Information'' section of this announcement.

Deadline: Applications shall be considered as meeting the deadline if they are either:

(a) Received on or before the deadline date; or

(b) Sent on or before the deadline date and received in time prior to the submission to the review panel. (Applicants must request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.)

Late Applications: Applications which do not meet the criteria in (a) or (b) above are considered late applications, will not be considered, and will be returned to the applicant.

G. Evaluation Criteria

Each application will be evaluated individually against the following criteria by an independent review group appointed by CDC.

1. Objectives

The degree to which the project objectives are capable of achieving the specific requirements defined in the program announcement. (25 points)

2. Plan

The degree to which the proposed activities described in the plan of operation, if well executed, are capable of attaining project objectives. The degree to which the applicant has met the CDC Policy requirements regarding the inclusion of women, ethnic, and racial groups in the proposed research. This includes: (a) The proposed plan for the inclusion of both sexes and racial and ethnic minority populations for appropriate representation, (b) the proposed justification when representation is limited or absent, (c) a statement as to whether the design of the study is adequate to measure differences when warranted, and (d) a statement as to whether the plans for recruitment and outreach for study participants include the process of establishing partnerships with community(ies) and recognition of mutual benefits. (25 points)

3. Evaluation

The degree to which the proposed plan of evaluation will adequately measure the objectives. (10 points)

4. Staff

The degree to which the current and proposed staff are appropriate for executing the project activities. (10 points)

5. Capacity

a. The degree to which organization demonstrates expertise in representing both the security and health aspects of a broad range of correctional facilities and activities (e.g., pre-release). (15 points)

b. Evidence of experience/history working with corrections in health, security, education, and training of inmates and staff. (15 points)

6. Budget

The degree to which the budget is reasonable, clearly justified, and consistent with the intended use of funds. (Not scored)

7 . Human Subjects

Does the application adequately address the requirements of 45 CFR part 46 for the protection of human subjects? (Not Scored)

____ YES ____ NO

Comments: _____

H. Other Requirements

Technical Reporting Requirements

Provide CDC with original plus two copies of

1. Quarterly Progress reports;

2. Financial status report, no more than 90 days after the end of the budget period; and

3. Final financial and performance reports, no more than 90 days after the end of the project period.

Send all reports to the Grants Management Specialist identified in the ''Where to Obtain Additional Information'' section of this announcement.

The following additional requirements are applicable to this program. For a complete description of each, see Attachment I in the application kit.

AR–1 Human Subjects Requirement
AR–2 Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research
AR–7 Executive Order 12372 Review
AR–9 Paperwork Reduction Act Requirements
AR–10 Smoke-Free Workplace Requirements
AR–11 Healthy People 2000
AR–12 Lobbying Restrictions
AR–15 Proof of Non-Profit Status

I. Authority and Catalog of Federal Domestic

Assistance Number

This program is authorized under sections 301(a) and 317(k)(1)of the Public Health Service Act, (42 U.S.C. sections 247b(k)(1) and 247b(k)(2)), as amended. The Catalog of Federal Domestic Assistance (CFDA) number is 93.283.

J. Where To Obtain Additional Information

To receive additional written information and to request an application kit, call 1–888–GRANTS4 (1–888–472–6874). You will be asked to leave you name and address and will be instructed to identify the Announcement number of interest.

If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from: Locke Thompson, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), Room 3000, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone: (404) 842–2749, Email address: lxt1@cdc.gov.

See also the CDC homepage on the Internet to obtain a copy of this announcement: http://www.cdc.gov

For program technical assistance, contact: Linda Moyer, Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Rickettsial Diseases, Hepatitis Branch, 1600 Clifton Rd, NE., Atlanta, GA 30333, Telephone: (404) 639–2709, E-mail address: lam1@cdc.gov.

Dated: June 4, 1999.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–14700 Filed 6–9–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99N–1590]

Merck & Co., Inc., et al.; Withdrawal of Approval of 32 New Drug Applications and 48 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 32 new drug applications (NDA's) and 48 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: JULY 12, 1999.

FOR FURTHER INFORMATION CONTACT: Olivia A. Pritzlaff, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

Application No.	Drug	Applicant
NDA 5–620	Mannitol Injection	Merck & Co., Inc., P.O. Box 4, BLA–20, West Point, PA 19486.
NDA 6–903	Milibis (glycobiarsol) Tablets	Sanofi Pharmaceuticals, Inc., 90 Park Ave., New York, NY 10016.
NDA 7–542	Tromexan Tablets	Novartis Pharmaceuticals Corp., 59 Route 10, East Hanover, NJ 07936–1080.
NDA 8–153	Dramamine (dimenhydrinate) Injection	G.D. Searle & Co., 4901 Searle Pkwy., Skokie, IL 60077.
NDA 8–843	Pro-Banthine (propantheline bromide) Injection	Do.
NDA 10–126	VapoSteam	Richardson-Vicks, 1 Far Mill Crossing, Shelton, CT 06484.
NDA 11–316	Temaril (trimeprazine tartrate) Tablets, Syrup, and Capsules	Allergan, 2525 Dupont Dr., P.O. Box 19534, Irvine, CA 92623–9534.
NDA 11–583	Hydeltrasol Injection	Merck & Co., Inc.
NDA 12–575	Actifed with Codeine (pseudoephedrine hydro-chloride, 30 milligrams (mg)/5 milliliters (mL), triprolidine hydrochloride, 25 mg/5 mL, codeine phosphate, 10 mg/5 mL)	Glaxo Wellcome Inc. 5 Moore Dr., P.O. Box 13398, Research Triangle Park, NC 27709.
NDA 13–553	Esimil (guanethidine monosulfate/hydro-chlorothiazide) Combination Tablets	Novartis Pharmaceuticals Corp.
NDA 15–865	Levoprome (methotrimeprazine) Injection	Immunex Corp., 51 University St., Seattle, WA 98101–2936.
NDA 16–349	10% Dextrose Injection	Baxter Healthcare Corp., Rte. 120 and Wilson Rd., Round Lake, IL 60073–0490.
NDA 16–717	10% Travert (invert sugar) Injection in PL 146 Container	Do.
NDA 16–938	Catarase (chymotrypsin intraocular solution) 1:5000 Ophthalmic Intraocular Solution	Ciba Vision Ophthalmics, 11460 John Creek Pkwy., Duluth, GA 30097–1556.
NDA 17–796	Byrel (piperazine citrate) Syrup	Sanofi Pharmaceuticals, Inc.